Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2021-11-29 Regulatory Filings
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
Bone Therapeutics et Link Health signent un accord non-contractuel pour les droits mondiaux d’ALLOB
Regulatory Filings Classification · 95% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE" (Press Release – Regulated Information) and announces a non-binding agreement between Bone Therapeutics and Link Health regarding global rights for the therapy ALLOB. This type of announcement, detailing a significant business development (licensing agreement, financial milestones, R&D cost assumption) released to the public and regulators on a specific date (November 29, 2021), fits best under the category of a general regulatory announcement or press release that doesn't strictly align with the detailed financial reports (10-K, IR) or specific corporate actions (DIV, SHA). It is not a full Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is not a proxy statement (DEF 14A) or a Director's Dealing report (DIRS). Since it is a formal, regulated announcement of a major business event, and it is not explicitly a report publication announcement (RPA) stating that a separate report is attached, the most appropriate general category for significant, non-standard regulatory news is Regulatory Filings (RNS).
2021-11-29 French
BOTHE_PR_2021-10-26_2021Q3_EN_Final.pdf
Earnings Release Classification · 98% confidence The document is explicitly labeled as a "PRESS RELEASE – REGULATED INFORMATION" and provides a "Business Update for the third quarter, ended 30 September 2021." It details operational highlights (clinical trial progress, study results), corporate highlights (management changes, financing), and financial highlights (cash position, cash burn, runway). This structure—a summary of recent operational and financial performance for a specific interim period (Q3 2021)—is characteristic of an Earnings Release (ER) or, given the comprehensive nature of the update, potentially an Interim/Quarterly Report (IR). However, the format is a press release summarizing key figures and events, rather than the full, detailed financial statements typically found in a formal Quarterly Report (IR). The content focuses on key results and business developments, aligning best with the definition of an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights only). It is not a full 10-K, an Audit Report (AR), or a mere announcement of a report (RPA/RNS). 9M 2021
2021-10-26 English
BOTHE_PR_2021-10-26_2021Q3_FR_Final.pdf
Earnings Release Classification · 100% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE" (Press Release – Regulated Information) and announces the company's financial results for the third quarter of 2021 ("Bone Therapeutics publie ses résultats du troisième trimestre 2021"). It provides key operational highlights, corporate developments, and financial figures for the period ending September 30, 2021. This structure—a formal announcement of period-specific financial performance highlights—is characteristic of an Earnings Release (ER). It is not the full, comprehensive report (which would be an IR or 10-K), nor is it a transcript (CT) or a general regulatory filing (RNS). The length (18,004 chars) suggests it contains substantial content, moving it beyond a simple RPA. 9M 2021
2021-10-26 French
Bone Therapeutics signs research partnership with Implant Therapeutics to access induced Pluripotent Stem Cells (iPSC)
Regulatory Filings Classification · 95% confidence The document is titled with a headline announcing a 'research partnership' and contains sections labeled 'PRESS RELEASE – REGULATED INFORMATION'. It details a strategic agreement between two companies (Bone Therapeutics and Implant Therapeutics) regarding cell technology access. This type of announcement, which details a significant business development, partnership, or strategic move, is typically classified as a general regulatory announcement or a specific corporate action announcement. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it is a formal press release, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a material event disclosure that doesn't fit the more specific categories like M&A (TAR) or Financing (CAP). It is a formal disclosure of a business event.
2021-09-28 English
Bone Therapeutics signe un partenariat de recherche avec Implant Therapeutics pour garantir son accès à des Cellules Souches Pluripotentes induites (CSPi)
Regulatory Filings Classification · 95% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE – INFORMATION REGLEMENTEE" (Press Release – Regulated Information) and is dated September 28, 2021. It announces a specific business event: a research partnership between Bone Therapeutics and Implant Therapeutics regarding induced Pluripotent Stem Cells (iPSCs). This type of announcement, detailing strategic business developments, partnerships, or material non-financial news released to the public, is typically classified as a general regulatory announcement or press release. Since there is no specific category for 'Partnership Announcement' and it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), the most appropriate general category for regulated, non-financial corporate news that must be disclosed is 'Regulatory Filings' (RNS), which serves as a broad category for miscellaneous regulatory announcements not covered elsewhere. The length (11,566 chars) suggests it is the full content, not just a brief announcement of a report (ruling 2 does not apply).
2021-09-28 French
Bone Therapeutics appoints Lieve Creten as interim Chief Financial Officer
Board/Management Information Classification · 99% confidence The document is explicitly titled as a 'PRESS RELEASE – REGULATED INFORMATION' and announces a specific management change: the appointment of Lieve Creten as interim Chief Financial Officer (CFO) and the transition of the previous CFO. This type of announcement, concerning changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information' (MANG). It is not a full financial report (10-K, IR), an earnings release (ER), or a presentation (IP).
2021-09-21 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.